Prekallikrein activator
Gallimore, M.J.; Friberger, P.
Thrombosis and Haemostasis 52(3): 366
1984
ISSN/ISBN: 0340-6245 PMID: 6335791 Document Number: 229967
Document emailed within 1 workday
Related Documents
Lämmle, B.; Lohri, A.; Tran, T.H.; Czendlik, C. 1984: Amidolytic prekallikrein (PK) assay: unsuitability of Cephotest as an activator Thrombosis and Haemostasis 51(2): 294Bakker, J.C.; de Vries-van Rossen, A.; Radema, H.; Bleeker, W.; Ufkes, J.G.; van Rosevelt, R.F.; van Mourik, J.A. 1983: Identification of a bradykinin-generating hypotensive substance in plasma protein fraction: prekallikrein activator (PKA-beta-Xiia) Advances in Experimental Medicine and Biology 156: 1091-1097
You, Q.-l.; Chen, W. 2002: A comparative study on clinical effectiveness of activator and Headgear-Activator Shanghai Kou Qiang Yi Xue 11(3): 237-239
Han, X.M.; Chen, Z.Q.; Mao, H.M. 1990: Determination of plasma tissue type plasminogen activator and plasminogen activator inhibitor activity in patients with ischemic stroke Zhonghua Nei Ke Za Zhi 29(9): 544-546; 575-576
Habib, S.S.; Abdel Gader, A.G.M.; Kurdi, M.I.; Suriya, M.O.; Al Aseri, Z. 2012: Tissue plasminogen activator and plasminogen activator inhibitor-1 levels in patients with acute myocardial infarction and unstable angina JPMA. Journal of the Pakistan Medical Association 62(7): 681-685
Yamada, R.; Yamada, S.; Ishii, A.; Tane, S. 1993: Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy Nippon Ganka Gakkai Zasshi 97(8): 955-960
De Moerloose, P.; Mermillod, N.; Amiral, J.; Reber, G. 1998: Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1 Thrombosis and Haemostasis 79(3): 554-556
Glas-Greenwalt, P.; Hall, J.M.; Panke, T.W.; Kant, K.S.; Allen, C.M.; Pollak, V.E. 1986: Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura Journal of Laboratory and Clinical Medicine 108(5): 415-422
Fukao, H.; Yamamoto, K.; Matsuo, O. 1991: Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome Rinsho Byori. Japanese Journal of Clinical Pathology 39(7): 720-726
Wallnöfer, A.E.; van Griensven, J.M.; Schoemaker, H.C.; Cohen, A.F.; Lambert, W.; Kluft, C.; Meijer, P.; Kooistra, T. 1993: Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans Thrombosis and Haemostasis 70(6): 1005-1008
Shiba, E.; Kobayashi, T.; Yayoi, E.; Takatsuka, Y.; Koyama, H.; Takai, S.; Mori, T. 1992: Measurement of plasminogen activator and plasminogen activator inhibitor in breast cancer tissue: preliminary report Nihon Geka Gakkai Zasshi 93(1): 109
Virji, M.A.; Aggarwal, S.; Kang, Y. 1989: Alterations in plasminogen activator and plasminogen activator inhibitor levels during liver transplantation Transplantation Proceedings 21(3): 3540-3541
Sollo, D.G.; Saleem, A. 1985: Prekallikrein (Fletcher factor) deficiency Annals of Clinical and Laboratory Science 15(4): 279-285
Marcel, G.A.; Caspar, C.; Sabatier, C.; Gautray, J.; Schirar, A. 1975: High prekallikrein levels during pregnancy Pathologie-Biologie 23 Suppl: 66-68
Kobayashi, Y.; Fukuo, Y.; Shibuya, T.; Terashi, A. 1990: The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 27(5): 578-583
Nelles, L.; Lijnen, H.R.; Van Nuffelen, A.; Demarsin, E.; Collen, D. 1990: Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA) Thrombosis and Haemostasis 64(1): 53-60
Harbeck, N.; Kates, R.E.; Look, M.P.; Meijer-Van Gelder, M.E.; Klijn, J.G.M.; Krüger, A.; Kiechle, M.; Jänicke, F.; Schmitt, M.; Foekens, J.A. 2002: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Research 62(16): 4617-4622
Fujii, S.; Lucore, C.L.; Hopkins, W.E.; Billadello, J.J.; Sobel, B.E. 1990: Induction of synthesis of plasminogen activator inhibitor type-1 by tissue-type plasminogen activator in human hepatic and endothelial cells Thrombosis and Haemostasis 64(3): 412-419
Wuillemin, W.A.; Furlan, M.; von Felten, A.; Lämmle, B. 1993: Functional characterization of a variant prekallikrein (PK Zürich) Thrombosis and Haemostasis 70(3): 427-432
De La Cadena, R.A.; Scott, C.F.; Colman, R.W. 1987: Evaluation of a microassay for human plasma prekallikrein Journal of Laboratory and Clinical Medicine 109(5): 601-607